REG - Diaceutics PLC - Senior Management Appointments

DiaceuticsAnnouncement

11/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240711:nRSK9478Va&default-theme=true

RNS Number : 9478V  Diaceutics PLC  11 July 2024

Diaceutics Makes Four Senior Management Appointments

VP Chief of Staff, VP of Human Resources, VP of Engagement Solutions and VP of
Real-World Data

New roles will further strengthen management team and drive continued
innovation, performance & growth at Diaceutics

 

Belfast and London, 11 July 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry, is
pleased to announce four appointments to its executive team. These
appointments are part of Diaceutics' commitment to strong governance and
ensuring it has the structure in place to capitalise upon the growth in its
market. The new Vice Presidents - Madeline Brown, Norma Thompson, Gosia
Leitch, and Scott Phillips - bring a wealth of experience and expertise to
their respective roles and will add significant strength to Diaceutics'
leadership team and as it drives continued innovation, performance and growth.

Diaceutics CEO Ryan Keeling said, "Madeline, Norma, Gosia, and Scott are
dynamic leaders whose extensive experience, vision and innovative approaches
will be crucial in shaping Diaceutics' future performance and growth. As we
continue to expand, their perspectives will be essential to helping us reach
our full potential."

Madeline Brown, VP, Chief of Staff

Madeline Brown has been with Diaceutics since 2007, holding significant roles
in finance and strategic project management. She will now lead the Chief
Executive's Office, focusing on driving efficiencies and scalability.

Norma Thompson, VP of Human Resources

Norma Thompson joined Diaceutics in 2019 as Global Head of Human Resources.
With over 30 years of experience, she brings extensive knowledge in HR
management, talent development, and regulatory environments, essential for
Diaceutics' global operations.

Gosia Leitch, VP of Engagement Solutions

Gosia Leitch has over 20 years of experience in diagnostics and pharma,
including roles at Veracyte, Abbott, Qiagen, Bayer Healthcare and SC Johnson.
She will drive engagement strategies connecting diagnostics with the broader
healthcare ecosystem.

Scott Phillips, VP of Real-World Data

Scott Phillips brings over 12 years of experience in real-world data, product
development, strategy consulting, and business development. Previously at
Komodo Health and COTA Healthcare, he will enhance Diaceutics' data strategy
and integration of real-world evidence.

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network®.

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison, Nick Harland, Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde, Kinvara Verdon, Kieran Breheny         diaceutics@almastrategic.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADZGMNRGDGDZM